Filing Details
- Accession Number:
- 0001213900-25-039888
- Form Type:
- 13D Filing
- Publication Date:
- 2025-05-05 20:00:00
- Filed By:
- Thomas Meyer
- Company:
- Altamira Therapeutics Ltd.
- Filing Date:
- 2025-05-06
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Thomas Meyer | 1,079,843 | 0 | 1,079,843 | 0 | 1,079,843 | 18.9% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 14)
|
Altamira Therapeutics Ltd. (Name of Issuer) |
Common Stock, par value $0.002 per share (Title of Class of Securities) |
G0360L134 (CUSIP Number) |
Thomas Meyer Clarendon House, 2 Church Street, Hamilton, D0, HM 11 1 441 295 59 50 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
04/30/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | G0360L134 |
| 1 |
Name of reporting person
Thomas Meyer | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
SWITZERLAND
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,079,843.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
18.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The foregoing beneficial ownership percentage is based upon 5,715,472 common shares, par value $0.002 per share (the "Common Shares") of Altamira Therapeutics Ltd., a Bermuda corporation (the "Issuer"), issued and outstanding as of April 30, 2025 based on information from the Issuer. The Reporting Person beneficially owns 1,079,843 Common Shares consisting of 1,074,312 Common Shares and warrants and options to purchase up to 5,531 Common Shares exercisable within sixty (60) days of the date hereof.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.002 per share | |
| (b) | Name of Issuer:
Altamira Therapeutics Ltd. | |
| (c) | Address of Issuer's Principal Executive Offices:
Clarendon House, 2 Church Street, Hamilton,
BERMUDA
, HM 11. | |
Item 1 Comment:
This Amendment No. 14 (the "Amendment") amends and supplements the Schedule 13D filed by the Reporting Person (as defined in the Schedule 13D) with the Securities and Exchange Commission (the "SEC") on April 3, 2018, as amended on July 23, 2018, as further amended on November 21, 2018, as further amended on June 13, 2018, as further amended on August 12, 2019, as further amended on August 20, 2020, as further amended on October 6, 2020, as further amended on December 4, 2020, as further amended on May 21, 2021, as further amended on May 12, 2022,as further amended on September 13, 2022, as further amended on January 18, 2023, as further amended on April 17, 2023 and as further amended on March 13, 2024 (the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. | ||
| Item 2. | Identity and Background | |
| (a) | N/A | |
| (b) | N/A | |
| (c) | N/A | |
| (d) | N/A | |
| (e) | N/A | |
| (f) | N/A | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: On April 30, 2025, in lieu of a cash bonus, the Reporting Person received 1,053,392 common shares, par value $0.002 per share (the "Common Shares"). Such share issuance was approved by the Compensation Committee of the Issuer. | ||
| Item 4. | Purpose of Transaction | |
N/A | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Item 5 of Schedule 13D is hereby amended and restated in full as follows: The information contained on the cover pages to the Schedule 13D is incorporated by reference herein. As of the date hereof, there are 5,715,472 Common Shares outstanding. The Reporting Person beneficially owns 1,079,843 Common Shares including Common Shares that the Reporting Person has the right to acquire within sixty (60) days of the date hereof upon exercise of outstanding options and warrants, representing 18,9% of the class. | |
| (b) | The Reporting Person holds sole power to vote and dispose over all of the Common Shares of the Issuer that he beneficially owns. | |
| (c) | The information provided in Item 3 and Item 4 of the Schedule 13D is incorporated by reference herein. Except as described herein, during the past sixty (60) days on or prior to April 30, 2025 (the "Event Date"), and from the Event Date to the date hereof, there were no other purchases or sales of Common Shares, or securities convertible into or exchangeable for Common Shares, by the Reporting Person or any person or entity for which the Reporting Person possesses voting or dispositive control over the securities thereof. | |
| (d) | Not applicable. | |
| (e) | Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
N/A | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|